Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers [0.03%]
新型缓激肽BAY 1142524在健康男性受试者中的药代动力学、安全性和耐受性研究报告
Friederike Kanefendt,Uwe Thuß,Michael Becka et al.
Friederike Kanefendt et al.
The orally available chymase inhibitor BAY 1142524 is currently being developed as a first-in-class treatment for left-ventricular dysfunction after myocardial infarction. Results from 3 randomized, single-center, phase 1 studies in healthy...
Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals [0.03%]
BTI320药理学Ⅰ期研究：餐前给药及对高血糖饮食的反应
David R Luke,Karen Ka Yan Lee,Carl W Rausch et al.
David R Luke et al.
BTI320 is a proprietary fractionated mannan polysaccharide being studied for attenuation of postprandial glucose excursion. The apparent blood glucose-lowering effect of this compound is effective in lowering postprandial hyperinsulinemia, ...
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects [0.03%]
米那洛肽与劳拉西泮、唑吡坦、曲马多或乙醇联合应用时的药代动力学、药效学、安全性和耐受性：健康志愿者中的药物相互作用研究结果
Mendel Jansen,Jeanne Mendell,Alexander Currie et al.
Mendel Jansen et al.
Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central...
Pharmacokinetics of Perampanel in Healthy Korean, White, and Japanese Adult Subjects [0.03%]
拉莫三嗪在健康韩国人、白种人和日本人受试者中的药代动力学研究
Hiroko Tabuchi,Sari Shiba,Sanae Yasuda et al.
Hiroko Tabuchi et al.
Perampanel is a highly selective, orally active, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist that has been approved in many countries as a treatment for partial-onset seizures and primary general...
Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers [0.03%]
氨内维：与蒙特鲁卡斯特和布普品在健康志愿者中的潜在CYP2C8及CYP2B6介导的药动学相互作用研究
Jeremy Dennison,Adeep Puri,Steven Warrington et al.
Jeremy Dennison et al.
Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8. We conducted 2 studies, 1 using montelukast as a probe to assess CYP2C8 and the other bupropion to assess CYP2B6. The montelukast study examined ...
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers [0.03%]
健康日本受试者单次口服GSK2330672后的安全性和耐受性、药代动力学和药效学研究
Hiroko Ino,Akira Endo,Akira Wakamatsu et al.
Hiroko Ino et al.
GSK2330672 is an inhibitor of the ileal bile acid transporter, designed to have minimal systemic exposure, and is under development as a potential therapeutic for pruritus associated with primary biliary cholangitis and other cholestatic li...
Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis [0.03%]
托法替尼治疗中重度慢性斑块状银屑病患者的药动学特征研究
Guangli Ma,Rujia Xie,Bruce Strober et al.
Guangli Ma et al.
Tofacitinib is an oral Janus kinase (JAK) inhibitor. This study characterized the pharmacokinetics of tofacitinib in patients with psoriasis and evaluated the impact of patient factors on disposition. Pooled phase 2/3 data (2981 patients: 9...
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors [0.03%]
用于晚期实体瘤患者的rucaparib药代动力学研究
Geoffrey I Shapiro,Rebecca S Kristeleit,Howard A Burris et al.
Geoffrey I Shapiro et al.
The phase 1-2 study CO-338-010 (Study 10; NCT01482715) is evaluating single-agent rucaparib, a poly(ADP-ribose) polymerase inhibitor, administered orally to patients with an advanced solid tumor. In the dose escalation phase (Part 1), we ch...
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease [0.03%]
拉奎尼莫德的全面QT/QTc研究-一种治疗多发性硬化症和亨廷顿舞蹈病的新型免疫调节剂
Ofer Spiegelstein,Dorit Mimrod,Laura Rabinovich et al.
Ofer Spiegelstein et al.
In this randomized double-blind study, 4 groups of healthy subjects (50 per arm) participated to evaluate the effect of laquinimod, an oral treatment in development for multiple sclerosis and Huntington disease, on the QTc interval. Subject...
Randomized Controlled Trial
Clinical pharmacology in drug development. 2019 Jan;8(1):49-59. DOI:10.1002/cpdd.442 2019
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects [0.03%]
评价恩格列净与西格列汀、二甲双胍、格列美脲或辛伐他汀在健康志愿者中相互作用的潜力
Vikas Kumar Dawra,David L Cutler,Susan Zhou et al.
Vikas Kumar Dawra et al.
Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of adults with type 2 diabetes mellitus, is expected to be coadministered with sitagliptin, metformin, glimepiride, and/or simvastatin. Four separate open-label, ra...